Millions of Americans with obesity could be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid.
Biden proposes Medicare and Medicaid cover costly weight-loss drugs for millions of obese Americans
Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid under a new Biden administration rule.
Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid under a new Biden administration rule.
Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid under a new Biden administration rule.
Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid under a new Biden administration rule.
WASHINGTON — Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by Medicare or Medicaid under a new rule the Biden administration proposed Tuesday morning.
The costly proposal from the U.S. Department of Health and Human Services immediately sets the stage for a showdown between the powerful pharmaceutical industry and Robert F. Kennedy Jr., an outspoken opponent of the weight-loss drugs who, as President-elect Donald Trump’s nominee to lead the agency, could block the measure.
While the rule would give millions of people access to weekly injectables that have helped people shed pounds so quickly that some have labeled them miracle drugs, it would cost taxpayers as much as $35 billion over the next decade.
